Argenx
ARGX
#582
Rank
NZ$59.64 B
Marketcap
$997.48
Share price
-0.86%
Change (1 day)
23.12%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : NZ$0.90 Billion

According to Argenx 's latest financial reports the company's total liabilities are NZ$0.90 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Argenx - Total liabilities on balance sheet (from 2021 to 2020)

Total liabilities by year

Year Total liabilities Change
2022-12-31NZ$0.50 B9.12%
2021-12-31NZ$0.46 B-55.16%
2020-12-31NZ$1.03 B44.34%
2019-12-31NZ$0.71 B814.69%
2018-12-31NZ$78.15 M48.45%
2017-12-31NZ$52.65 M-22.24%
2016-12-31NZ$67.71 M346.41%
2015-12-31NZ$15.16 M-4.66%
2014-12-31NZ$15.9 M107.23%
2013-12-31NZ$7.67 M-23.95%
2012-12-31NZ$10.09 M50.07%
2011-12-31NZ$6.72 M92.3%
2010-12-31NZ$3.49 M